CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Levodopa / carbidopa (Drug Plan Submission)

Last Updated: January 9, 2019
Result type: Reports
Project Number: SR0557-000
Product Line: Reimbursement Review

Generic Name: Levodopa / carbidopa (Drug Plan Submission)

Brand Name: Duodopa

Manufacturer: AbbVie Corporation

Therapeutic Area: Parkinson's disease

Indications: Parkinson's disease

Manufacturer Requested Reimbursement Criteria1: Not applicable. Drug plan submission.

Submission Type: Drug Plan Initiated

Project Status: Complete

Biosimilar: No

Date Recommendation Issued: August 22, 2018

Recommendation Type: Reimburse with clinical criteria and/or conditions

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input posted January 11, 2018
Patient group input closed March 02, 2018

- Patient input submission received

Patient input summary sent for review to patient input groups March 14, 2018
Patient group comments on input summary closed March 21, 2018

- Patient input summary feedback received

Submission received February 08, 2018
Submission accepted for review February 23, 2018
Review initiated February 26, 2018
Draft CDR review report(s) sent to applicant May 10, 2018
Comments from applicant on draft CDR review report(s) received May 22, 2018
Redaction requests from applicant on draft CDR review report(s) received May 29, 2018
CDR review team's comments on draft CDR review report(s) sent to applicant July 06, 2018
Canadian Drug Expert Committee (CDEC) meeting July 18, 2018
CDEC recommendation & redacted CDR review report(s) sent to applicant and drug plans July 31, 2018
Embargo period ended and validation of redacted CDR review report(s) received August 15, 2018
CDEC Final Recommendation issued to applicant and drug plans August 22, 2018
CDEC Final Recommendation posted August 24, 2018
Final CDR review report(s) and patient input posted September 18, 2018